nyuuzyou/wikis huggingface dataset:
Toledo Vipers

Toledo Vipers 	Toledo Vipers
Current Season 	Current Season
 	
 	
 	
Established 	Season I
Conference 	Professional Football Conference
Stadium 	Glassner Arena
 	
History 	Toledo Vipers (Season I—present)
Uniform 	Uniform
 	
 	
Team Colors 	Reptile Green, Orange, White </br>              
Front Office 	Front Office
Franchise</br>Owner 	Wilson
Head</br>Coach 	N/A
Assistant</br>Coaches 	N/A
Postseason History 	Postseason History
Elite BowlChampionships	0
ConferenceChampionships	0
PlayoffBerths 	0
 	
Group Link 	https://web.roblox.com/Groups/group.aspx?gid=2578827
The Toledo Vipers are a professional American ro-football team that competes in the Elite Football League (EFL) as a member of the Professional Football Conference (PFC). The Vipers were founded during the inaugural season of the Elite Football League, thus making them members of the Original Eight teams that competed during Season I. They are currently being coached by Wilson. They play their home games at Glassner Arena.
Tulsa Titans

Tulsa Titans 	Tulsa Titans
Current Season 	Current Season
 	
 	
 	
Established 	Season I
Conference 	Legendary Football Conference
Stadium 	Leo Stadium
 	
History 	Canton Bulldogs (Season I)</br>Tulsa Titans (Season I—present)
Uniform 	Uniform
 	
 	
Team Colors 	Cobalt Blue, Light Blue, White </br>              
Front Office 	Front Office
Franchise</br>Owner 	MarkezTheBoy
Head</br>Coach 	quantumclips
Assistant</br>Coaches 	N/A
Postseason History 	Postseason History
Elite BowlChampionships	0
ConferenceChampionships	0
PlayoffBerths 	0
 	
Group Link 	https://www.roblox.com/Groups/group.aspx?gid=3151882
The Tulsa Titans (formerly known as the Canton Bulldogs before the start of Season I) are a professional American ro-football team that competes in the Elite Football League (EFL) as a member of the Legendary Football Conference (LFC). The Titans were founded during the inaugural season of the Elite Football League, thus making them members of the Original Eight teams that competed during Season I. They are currently being coached by prxncejakahi. They play their home games at Leo Stadium.
Category:Teams
VTyIer

vTyIer 	vTyIer
 	
Position 	Quarterback</br>Cornerback
Account Information 	Account Information
Join Date 	March 6, 2016
League Status 	Active
Career History 	Career History
Washington State Panthers (Season I–present)	Washington State Panthers (Season I–present)
Career Statistics (QB) 	Career Statistics (QB)
Completions 	11
Passing Yards 	172
Passer Rating 	136.7
Passing Touchdowns 	5
Interceptions 	1
vTyIer (also known as NegativeViibez and fourzeroeleven; joined March 6, 2016) is a quarterback and cornerback currently playing for the Washington State Panthers. He has been playing for the Panthers since Season I of the EFL. He is responsible for throwing the first ever touchdown pass in league history; a 26-yard strike to wide receiver A_ccelerations. He currently leads the league in every quarterback statistic, including touchdown passes and completions.
Walker Stadium

Walker Stadium 	Walker Stadium
 	
Basic Information 	Basic Information
Developer 	Vocain and MoseyReborn
Scripter 	Sporwn
Opened 	May 29, 2018
History 	Walker Stadium (Season I—present)
Tennant 	Tennant
Washington State Panthers (Season I—present)	Washington State Panthers (Season I—present)
Walker Stadium is the current home stadium of the Washington State Panthers. It has served as the Panthers home field since their conception in Season I. The stadium was built by Vocain and MoseyReborn and officially opened on May 29, 2018.
Washington State Panthers

Washington State Panthers	Washington State Panthers
Current Season 	Current Season
 	
 	
 	
Established 	Season I
Conference 	Legendary Football Conference
Stadium 	Walker Stadium
 	
History 	Washington State Panthers (Season I—present)
Uniform 	Uniform
 	
 	
Team Colors 	Scarlet, Black, White </br>              
Front Office 	Front Office
Franchise</br>Owner 	Deep_Patel
Head</br>Coach 	OnJerkNem
Assistant</br>Coaches 	MikeATL
Postseason History 	Postseason History
Elite BowlChampionships 	1 (Elite Bowl I)
ConferenceChampionships 	1 (Season I)
PlayoffBerths 	2 (Season I, Season II)
 	
Group Link 	https://www.roblox.com/Groups/group.aspx?gid=1244365
The Washington State Panthers are a professional American ro-football team that competes in the Elite Football League (EFL) as a member of the Legendary Football Conference (LFC). The Panthers were founded during the inaugural season of the Elite Football League, thus making them members of the Original Eight teams that competed during Season I. They are currently being coached by vTyler. They play their home games at Walker Stadium.
The Panthers have the distinction of being the first ever Elite Bowl champions, defeating the Canton Bulldogs by a score of 54-27 in the inaugural championship game to become the Season I champions. To this day, this remains the only championship won by the franchise.
Category:Teams
WhyAreUMad

WhyAreUMad 	WhyAreUMad
 	
Position 	Quarterback
Account Information 	Account Information
Join Date 	July 22, 2012
League Status 	Active
Career History 	Career History
Conway Tigers (Season I–present)	Conway Tigers (Season I–present)
Career Statistics (QB) 	Career Statistics (QB)
Completions 	5
Passing Yards 	78
Passer Rating 	67.1
Passing Touchdowns 	2
Interceptions 	2
WhyAreUMad (joined July 22, 2012) is a quarterback currently playing for the Conway Tigers of the Legendary Football Conference (LFC). He has been playing for the Tigers since Season I of the EFL. He was the first quarterback to ever start a game for Conway. He is also credited as being the quarterback who threw the first touchdown pass in Tigers franchise history against the Washington State Panthers in Week 1 of Season I.
XXXShockyy

XXXShockyy 	XXXShockyy
 	
Position 	Quarterback
Account Information 	Account Information
Join Date 	June 24, 2015
League Status 	Active
Career History 	Career History
Oakland Knights (Season I–present)	Oakland Knights (Season I–present)
Career Statistics 	Career Statistics
Completions 	7
Passing Yards 	123
Passer Rating 	70.1
Passing Touchdowns 	1
Interceptions 	2
XXXShockyy (joined June 24, 2015) is a quarterback currently playing for the Oakland Knights of the Legendary Football Conference (LFC). He has been playing for the Knights since Season I of the EFL. He was the first quarterback to ever start a game for Oakland.
Ycino

Ycino 	Ycino
 	
Development Team 	Development Team
Incumbent</br>February 14, 2017 – present	Incumbent</br>February 14, 2017 – present
 	
Preceded by 	Position established
Succeeded by 	ChicNjoku
No. 8 	No. 8
Position 	Defensive end</br>Tight end
Account Information 	Account Information
Join Date 	June 12, 2013
League Status 	Active
Career History 	Career History
Oakland Knights (Season I) 	Oakland Knights (Season I)
Ycino (joined June 12, 2013; formerly known as Vocain and URGames) is a stadium developer and graphic designer who is currently employed as a member of the EFL Development Team. He, alongside MoseyReborn, developed most of the team venues and stadiums, thumbnails and other league assets. He is considered one of the pioneers of the Elite Football League as well as one of the founders. He played during Season I as a defensive and tight end for the Oakland Knights. He retired from the league on August 22, 2018, but returned just before Elite Bowl I and continues to help develop assets for the league.
Yungpopper

yungpopper 	yungpopper
 	
Account Information	Account Information
Join Date 	August 24, 2017
League Status 	Retired
yungpopper (joined August 24, 2017) was the second head coach of the Conway Tigers. He was given the head coaching job after the resignation of NoRelease after Week 1 of Season I. He, just like his predecessor, resigned his head coaching position after only one week. He was subsequently replaced by JamesParkerIII.
ADAMTS13, recombinant (Adzynma)

==Mechanism of action==
Replacement therapy
==Diseases for which it is established==
*Congenital thrombotic thrombocytopenic purpura
==Diseases for which it is used==
*Acquired thrombotic thrombocytopenic purpura
==History of changes in FDA indication==
*2023-11-09: Approved for prophylactic (preventive) or on demand enzyme replacement therapy (ERT) in adult and pediatric patients with congenital thrombotic thrombocytopenic purpura (cTTP).
==Also known as==
*Brand name: Adzynma
Category:Drugs
Category:Intravenous medications
Category:Acquired thrombotic thrombocytopenic purpura medications
Category:Congenital thrombotic thrombocytopenic purpura medications
Category:Recombinant medications
Category:Hematology medications
Category:FDA approved in 2023
Abarelix (Plenaxis)

==Mechanism of action==
From the NCI Drug Dictionary: A synthetic decapeptide and antagonist of naturally occurring gonadotropin-releasing hormone (GnRH). Abarelix directly and competitively binds to and blocks the gonadotropin releasing hormone receptor in the anterior pituitary gland, thereby inhibiting the secretion and release of luteinizing hormone (LH) and follicle stimulating hormone (FSH).
==Diseases for which it is used==
*Prostate cancer
==History of changes in FDA indication==
*2003-11-25: Approved for palliative treatment of men with advanced symptomatic prostate cancer, in whom LHRH agonist therapy is not appropriate and who refuse surgical castration, and have one or more of the following: risk of neurological compromise due to metastases, ureteral or bladder outlet obstruction due to local encroachment or metastatic disease, or severe bone pain from skeletal metastases persisting on narcotic analgesia. (Based on Koch et al. 2003)
== Manufacturer Package Insert==
*Abarelix (Plenaxis) Package InsertAbarelix (Plenaxis) Package Insert
==Also known as==
*Brand name: Plenaxis
==References==
Category:Drugs
Category:Intramuscular medications
Category:GnRH antagonists
Category:Prostate cancer medications
Category:FDA approved in 2003
Abciximab (ReoPro)

==General information==
Class/mechanism: the Fab fragment of the chimeric human-murine monoclonal antibody 7E3, which binds to the glycoprotein IIb/IIIa receptor on platelets, preventing them from binding to fibrinogen, von Willebrand factor, and other adhesion molecules and thereby inhibiting platelet aggregation.
Route: IV
Extravasation: n/a
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias or the prescribing information.
==History of changes in FDA indication==
*1994-12-22: Initial approval (label not available at Drugs @ FDA)
==Also known as==
*Brand names: Clotinab, ReoPro
Category:Drugs
Category:Intravenous medications
Category:GPIIb-IIIa inhibitors
Category:anti-GPIIb-IIIa antibodies
Category:FDA approved in 1994
Abexinostat (PCI-24781)

==Mechanism of action==
From the NCI Drug Dictionary: A novel, broad-spectrum hydroxamic acid-based inhibitor of histone deacetylase (HDAC) with potential antineoplastic activity. Abexinostat inhibits several isoforms of HDAC, resulting in an accumulation of highly acetylated histones, followed by the induction of chromatin remodeling; the selective transcription of tumor suppressor genes; and the tumor suppressor protein-mediated inhibition of tumor cell division and induction of tumor cell apoptosis.
==Preliminary data==
Note: This is not meant to be an exhaustive list of preliminary results. References included in this section include non-randomized studies published in high-profile journals (e.g., NEJM) and experimental arms of phase 3 RCTs. Inclusion here is not an indication of impending regulatory approval, although many of these drugs do end up receiving approval by a regulatory authority.
===Lymphoma===
# PCYC-0403: Evens AM, Balasubramanian S, Vose JM, Harb W, Gordon LI, Langdon R, Sprague J, Sirisawad M, Mani C, Yue J, Luan Y, Horton S, Graef T, Bartlett NL. A Phase I/II Multicenter, Open-Label Study of the Oral Histone Deacetylase Inhibitor Abexinostat in Relapsed/Refractory Lymphoma. Clin Cancer Res. 2016 Mar 1;22(5):1059-66. Epub 2015 Oct 19. link to original article EuroPMC NCT00724984
# Ribrag V, Kim WS, Bouabdallah R, Lim ST, Coiffier B, Illes A, Lemieux B, Dyer MJ, Offner F, Felloussi Z, Kloos I, Luan Y, Vezan R, Graef T, Morschhauser F. Safety and efficacy of abexinostat, a pan-histone deacetylase inhibitor, in non-Hodgkin lymphoma and chronic lymphocytic leukemia: Results of a phase 2 study. Haematologica. 2017 May;102(5):903-909. Epub 2017 Jan 25. link to original article link to PMC article EuroPMC EudraCT-2009-013691-47
==Also known as==
*Code name: PCI-24781
Category:Drugs
Category:Oral medications
Category:HDAC inhibitors
Category:Lymphoma medications (investigational)
Category:Investigational drugs
Academic Medicine exhibit

The purpose of this page is to illustrate the difference between a "standard" longitudinal medical narrative and a "wiki-based" narrative; this exhibit is supplementary to the manuscript It’s Time to Wikify Clinical Documentation: How Collaborative Authorship Can Reduce the Burden and Improve the Quality of the Electronic Health Record. This narrative is based on a synthetic patient developed for the DeepPhe natural language processing project (U24 CA184407 from the National Cancer Institute at the US National Institutes of Health). 
*Standard narrative
*Wiki-based narrative
===References===
# Savova GK, Tseytlin E, Finan S, Castine M, Miller T, Medvedeva O, Harris D, Hochheiser H, Lin C, Chavan G, Jacobson RS. DeepPhe: a natural language processing system for extracting cancer phenotypes from clinical records. Cancer Res. 2017 Nov 1;77(21):e115-e118. link to original article link to PMC article EuroPMC
# Warner JL, Smith J, Wright A. It’s Time to Wikify Clinical Documentation: How Collaborative Authorship Can Reduce the Burden and Improve the Quality of the Electronic Health Record. Acad Med. 2019 May;94(5):645-650. link to original article EuroPMC
Category:Null pages
Acetaminophen (Tylenol)

==General information==
Class/mechanism: Antipyretic / Not completely understood. The main mechanism proposed is the inhibition of cyclooxygenase (COX), and recent findings suggest that it is highly selective for COX-2.
Routes: PO, PR
Extravasation: N/A
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias or the prescribing information.
==Diseases for which it is used==
No known antineoplastic properties. Used as a supportive medications especially prior to blood product and biologic product (e.g. monoclonal antibody) infusions.
==Also known as==
*Generic names: APAP, paracetamol, paracetamole
*Brand names: Calpol, Panadol, Tylenol
Category:Drugs
Category:Oral medications
Category:Rectal medications
Category:Antipyretics
Category:FDA approved in 1951
Category:OTC medications
Category:WHO Essential Pain and Palliative Care Medicine
Aclarubicin (Aclacinon)

==General information==
Class/mechanism from NCI Drug Dictionary: An oligosaccharide anthracycline antineoplastic antibiotic isolated from the bacterium Streptomyces galilaeus. Aclarubicin intercalates into DNA and interacts with topoisomerases I and II, thereby inhibiting DNA replication and repair and RNA and protein synthesis. Aclarubicin is antagonistic to other agents that inhibit topoisomerase II, such as etoposide, teniposide and amsacrine.
Route: IV
Extravasation: irritant
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias or the prescribing information.
==Diseases for which it is used==
*Acute myeloid leukemia
==Patient drug information==
No information available.
==Also known as==
*Code name: MA144-A1
*Generic names: aclacinomycin, aclacinomycin A, aclacinomycin A hydrochloride, aclacinomycin-A, aclarubicin hydrochloride
*Brand names: Aclacin, Aclacinomycine, Aclacinon, Aclaplastin, Jaclacin
==References==
Category:Drugs
Category:Intravenous medications
Category:Anthracyclines
Category:Topoisomerase I inhibitors
Category:Topoisomerase II inhibitors
Category:Acute myeloid leukemia medications
Category:PMDA approved drugs
Actinium Ac 225 lintuzumab (Actimab-A)

==Mechanism of action==
Monoclonal antibody directed against CD33 with a radioactive agent attached.
==Also known as==
*Brand name: Actimab-A
Category:Drugs
Category:Intravenous medications
Category:Radiotherapy medications
Category:Anti-CD33 radioimmunoconjugates
Category:Acute myeloid leukemia medications (investigational)
Category:Investigational drugs
Acute lymphoblastic leukemia, infant - historical

Back to Top
The purpose of this page is to provide references to regimens that are obsolete, outdated, or of historical interest only. Is there a regimen missing from this list? See the main pediatric B-ALL page for current regimens.
Last updated on 2024-07-23:1 regimens on this page
1 variants on this page
 
=Induction=
==Cytarabine, Daunorubicin, L-Asparaginase, Vincristine, Dexamethasone==
===Regimen===
Study 	Dates of enrollment	Evidence
Pieters et al. 2007 (Interfant-99)	1999-2005 	Non-randomized part of RCT
Pieters et al. 2019 (Interfant-06)	2006-02 to 2016-07 	Non-randomized part of phase 3 RCT
Note: this regimen is listed as historic primarily due to the unavailability of L-asparaginase. Note that the timing takes into account the week-long pre-phase (i.e., induction starts on day 8).
====Preceding treatment====
*Prednisone pre-phase
====Chemotherapy====
*Cytarabine (Ara-C) 75 mg/m2 IV over 30 minutes once per day on days 8 to 21
*Daunorubicin (Cerubidine) 30 mg/m2 IV over 60 minutes once per day on days 8 & 9
*Asparaginase (Elspar) 5000 units/m2 IV over 60 minutes once per day on days 15, 18, 22, 25, 29, 33
*Vincristine (Oncovin) 1.5 mg/m2 IV push once per day on days 8, 15, 22, 29
====Glucocorticoid therapy====
*Dexamethasone (Decadron) 6 mg/m2/day PO or IV on days 8 to 29, then tapered off over days 30 to 36
28-day course
====Subsequent treatment====
*Interfant-99: MARAM consolidation
*Interfant-06: MARMA versus ADE consolidation
===References===
# Interfant-99: Pieters R, Schrappe M, De Lorenzo P, Hann I, De Rossi G, Felice M, Hovi L, LeBlanc T, Szczepanski T, Ferster A, Janka G, Rubnitz J, Silverman L, Stary J, Campbell M, Li CK, Mann G, Suppiah R, Biondi A, Vora A, Valsecchi MG. A treatment protocol for infants younger than 1 year with acute lymphoblastic leukaemia (Interfant-99): an observational study and a multicentre randomised trial. Lancet. 2007 Jul 21;370(9583):240-250. link to original article EuroPMC NCT00015873
# Interfant-06: Pieters R, De Lorenzo P, Ancliffe P, Aversa LA, Brethon B, Biondi A, Campbell M, Escherich G, Ferster A, Gardner RA, Kotecha RS, Lausen B, Li CK, Locatelli F, Attarbaschi A, Peters C, Rubnitz JE, Silverman LB, Stary J, Szczepanski T, Vora A, Schrappe M, Valsecchi MG. Outcome of Infants Younger Than 1 Year With Acute Lymphoblastic Leukemia Treated With the Interfant-06 Protocol: Results From an International Phase III Randomized Study. J Clin Oncol. 2019 Sep 1;37(25):2246-2256. Epub 2019 Jul 8. link to original article dosing details in supplement have been reviewed by our editors EuroPMC NCT00550992
Category:Acute lymphoblastic leukemia, infant regimens
Category:Acute lymphoblastic leukemias
Category:Historical regimens
Category:Disease-specific pages
Category:Pediatric hematologic neoplasms
Acute myeloid leukemia trial demographics

Study 	Arm 	Age, median (range)	Sex (%M/%F)	Race 	Performance Status
Wiernik et al. 1992 	7+3d (standard-dose)	55 (NR) 	57/43 	Not reported	ECOG 0-1: 86%
Wiernik et al. 1992 	7+3i 	56 (NR) 	56/44 	Not reported	ECOG 0-1: 87%
ECOG E1900 	7+3d (standard-dose)	47 (17-60) 	52/48 	Not reported	Not reported
ECOG E1900 	7+3d (high-dose) 	48 (18-60) 	50/50 	Not reported	Not reported
HOVON 43 AML/SAKK 30/01	7+3d (standard-dose)	67 (60-79) 	57/43 	Not reported	ECOG 0-1: 88%
HOVON 43 AML/SAKK 30/01	7+3d (high-dose) 	67 (60-83) 	53/47 	Not reported	ECOG 0-1: 88%
ADcomparison 	7+3d (standard-dose)	43 (15-60)a 	48/52 	Not reported	KPS 90-100%: 80%
ADcomparison 	7+3d (high-dose) 	43 (15-60)a 	60/40 	Not reported	KPS 90-100%: 82.5%
aAge is not reported separately by arm.
This work is supported in part by NCI U24 CA265879.
Category:General reference pages
Acyclovir (Zovirax)

==General information==
Class/mechanism: Antiviral; synthetic purine nucleoside analog which interacts with the viral thymidine kinase (TK) encoded by herpes simplex virus types 1 and 2 (HSV-1 & HSV-2) and the varicella-zoster virus (VZV). Thymidine kinase converts acyclovir to acyclovir monophosphate, which is eventually converted via phosphorylation into acyclovir triphosphate. Acyclovir triphosphate inhibits the replication of viral DNA by prematurely terminating the replicating DNA strand since acyclovir has no 3' end; competitively inhibiting viral DNA polymerase; and inactivating viral DNA polymerase. Acyclovir has greater activity against HSV compared to VZV because of more robust phosphorylation by the HSV viral thymidine kinase.Acyclovir (Zovirax) package insert Acyclovir (Zovirax) package insert (locally hosted backup)
Route: PO, IV, topical
Extravasation: no information
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, UpToDate Lexidrug, Medscape, or the prescribing information.
==Diseases for which it is used==
No known antineoplastic properties. Widely used to prevent HSV and VZV reactivation in immunocompromised hosts receiving chemotherapy.
==Patient drug information==
*Acyclovir (Zovirax) patient drug information (RxList)Acyclovir (Zovirax) patient drug information (RxList)
*Acyclovir (Zovirax) patient drug information (UpToDate)Acyclovir (Zovirax) patient drug information (UpToDate)
==Also known as==
*Generic names: aciclovir, ACV, acycloguanosine
*Brand names:
Synonyms 	Synonyms	Synonyms 	Synonyms	Synonyms 	Synonyms 	Synonyms	Synonyms
Acic 	Acivir 	Acivirax 	Acylete 	Apo-acyclovir	Avorax 	Axcel 	
Cusiviral	Cyclovax	Cyclovir 	Declovir	Dravyr 	Hepirax 	Herpevex	
Herpex 	Herzovir	Klovireks-l	Lovir 	Medovir 	Pharmaniaga	Saforax 	
Vacrax 	Vicide 	Virax 	Virest 	Virless 	Virox 	Virucid 	
Virupos 	Xovir 	Zevin 	Zirax 	Zoral 	Zorax 	Zoraxin 	
Zoviax 	Zovir 	Zovirax 	 	 	 	 	
==References==
Category:Drugs
Category:Oral medications
Category:Intravenous medications
Category:Topical medications
Category:Antivirals
Category:FDA approved in 1982